Tesamorelin
Approved medicineGet notified when the evidence changes.
The FDA has approved a version of this as a medicine, so it has been through large studies in people.
Compiled and reviewed by the PeptideSearch Editorial Team · Status checked 2026-06-05
Also called Egrifta / TH9507 / GRF 1-44 analogue
A copy of the natural growth hormone signal, approved to reduce deep belly fat in people living with HIV.
The basics
- What is it?
- An approved medicine that copies the natural brain signal for releasing growth hormone.
- What do we know?
- In people living with HIV who carry extra deep belly fat, it reduces that fat. That is what it is approved for.
- What do we still not know?
- Whether it helps anyone outside that specific group.
Watch: what the research shows
Tesamorelin: What The Research Actually Shows
FDA approved. It took 23 human studies, 17 trials and 20 years — and it bought an approval for one condition, in one group of people.
Official status: Pharmacies may compound it · Checked 2026-06-05
Can a doctor prescribe this?
- Small pharmacy (503A)
- Never put forward to FDA
- Large outsourcing facility (503B)
- Never put forward to FDA
FDA approved for HIV-associated lipodystrophy and legally available by prescription.
Why both lines above can be true: this compound is the active ingredient of a drug the FDA has already approved, and a pharmacy may compound with a bulk substance that is “a component of a drug approved by the Secretary” — a separate route in the law from the list of substances put forward for review. So it never had to be nominated for that list. The wording is in section 503A(b)(1)(A)(i)(II) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 353a). The substance must also be made by an FDA-registered establishment and come with a certificate of analysis for each lot.
503A is a pharmacy making a single prescription for one patient. 503B is a facility making batches. They are governed by separate lists. Where a category is shown, it is a position on the FDA's list of substances that have been put forward and are still being worked through — not the final list, which is set by rulemaking. Category 1 means the FDA does not plan to act against a pharmacy that makes it while the review runs.
Lab suppliers we list: 15
Doses used in research
Taken word for word from the studies and trials listed on this page. This is not a recommendation and not a dose for anyone to take.
- Study in peopleTesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH): a clinical trial protocol.
BMJ open · 2026
- Study in peopleEffects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity.
The Journal of infectious diseases · 2025
- Study in peopleEfficacy and safety of tesamorelin in people with HIV on integrase inhibitors.
AIDS (London, England) · 2024
- Study in peopleEffect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trial.
Journal of clinical and translational science · 2023
- Study in peopleGrowth Hormone Releasing Hormone Reduces Circulating Markers of Immune Activation in Parallel with Effects on Hepatic Immune Pathways in Individuals with HIV-infection and Nonalcoholic Fatty Liver Disease.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021
- Study in peopleClinical Predictors of Liver Fibrosis Presence and Progression in Human Immunodeficiency Virus-Associated Nonalcoholic Fatty Liver Disease.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021
- Study in peopleEffects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD.
JCI insight · 2020
- Study in peopleEffects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.
The lancet. HIV · 2019
- Study in peopleFibroblast growth factor 21 decreases after liver fat reduction via growth hormone augmentation.
Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2017
- Study in peopleSafety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial.
PloS one · 2017
- Study in peoplePredictors of Treatment Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat.
PloS one · 2015
- Study in peopleEffect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial.
JAMA · 2014
- Study in peopleThe effects of tesamorelin on phosphocreatine recovery in obese subjects with reduced GH.
The Journal of clinical endocrinology and metabolism · 2014
- Study in peopleMetabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial.
The Journal of clinical endocrinology and metabolism · 2012
- Study in peopleReduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2012
- Study in peopleEffects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction.
AIDS (London, England) · 2011
- Study in peopleEffects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.
Journal of acquired immune deficiency syndromes (1999) · 2010
- Study in peopleLong-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation.
AIDS (London, England) · 2008
- Study in peopleMetabolic effects of a growth hormone-releasing factor in patients with HIV.
The New England journal of medicine · 2007
- Study in peopleA placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation.
AIDS (London, England) · 2005
- Data from people, not a trialDiffering Presentations of Excess Visceral Abdominal Fat in People Living With HIV: Two Clinical Cases Highlighting Distinct Therapeutic Pathways With Tesamorelin and Glucagon-Like Peptide-1 Receptor Agonists.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
- Data from people, not a trialCarpal Tunnel Syndrome Attributed to Medication Use: A Pharmacovigilance Study.
Cureus · 2025
- Data from people, not a trialPharmacoeconomic Review Report: Tesamorelin (Egrifta)
2016
- Animal study, rats or miceCombined antiretroviral therapy with low- or normal-protein, high-calorie diets appears to induce significant deleterious electrocardiographic changes in a rodent model.
Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas · 2026
- Testing of products for sale, not a health studyEvaluation of Research Grade Peptides Marketed Directly to Consumers Reveals Extensive Variability in Purity and Measured Abundance
2026
- Lab test method, not a health studyAnalysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry.
Journal of pharmaceutical and biomedical analysis · 2026
- Lab test method, not a health studyChromatographic-mass spectrometric analysis of peptidic analytes (2-10 kDa) in doping control urine samples.
Journal of mass spectrometry : JMS · 2024
- Lab test method, not a health studyCationic exchange SPE combined with triple quadrupole UHPLC-MS/MS for detection of GHRHs in urine samples.
Analytical biochemistry · 2023
- Drug information page, not a studyCADTH Canadian Drug Expert Committee Final Recommendation: Tesamorelin: (Egrifta — Theratechnologies Inc.): Indication: HIV-associated lipohypertrophy
2016
- The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV.
The Journal of frailty & aging · 2019
- Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects.
Clinical pharmacokinetics · 2015
- Population pharmacokinetic and pharmacodynamic analysis of tesamorelin in HIV-infected patients and healthy subjects.
Journal of pharmacokinetics and pharmacodynamics · 2015
- Relationship of adiponectin to endogenous GH pulse secretion parameters in response to stimulation with a growth hormone releasing factor.
Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2011
- Review of earlier workBody composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials.
Obesity research & clinical practice · 2026
- Review of earlier workInjectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.
The American journal of sports medicine · 2026
- Review of earlier workSafety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.
Sports medicine (Auckland, N.Z.) · 2026
- Review of earlier workEfficacy and Safety of Tesamorelin in People Living With HIV (PLWH) With Lipodystrophy: A Systematic Review and Meta-Analysis.
Journal of the International Association of Providers of AIDS Care · 2026
- Review of earlier workThe emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.
Frontiers in endocrinology · 2026
- Review of earlier workPharmacologic Treatments for the Preservation of Lean Body Mass During Weight Loss.
Journal of clinical medicine · 2026
- Review of earlier workInjectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications.
JBJS reviews · 2026
- Review of earlier workPeptides in Regenerative Medicine: Mechanisms, Evidence, and Translational Status
2026
- Review of earlier workTherapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.
Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · 2026
- Review of earlier workMetabolic dysfunction-associated steatotic liver disease in people with HIV.
Current opinion in HIV and AIDS · 2025
- Review of earlier workCROI 2024: Neuropsychiatric Complications in People With HIV.
Topics in antiviral medicine · 2024
- Review of earlier workClinical Review Report: Tesamorelin (Egrifta)
2016
- Study in peopleThe effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment.
eNeurologicalSci · 2026
- Study in peopleGrowth hormone-releasing hormone effects on brain γ-aminobutyric acid levels in mild cognitive impairment and healthy aging.
JAMA neurology · 2013
- Study in peopleEffects of growth hormone–releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial.
Archives of neurology · 2012
Spot an error? corrections@peptidesearch.org